Get started
Cytosorbents CorporationCytosorbents CorporationCytosorbents Corporation

Cytosorbents Corporation

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

CTSO chart


Full chart

CTSO upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪54.53 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.3804 USD
Net income (FY)
‪−20.72 M‬ USD
Revenue (FY)
‪35.59 M‬ USD
Shares float
‪51.92 M‬
Beta (1Y)
0.24

Employees


Employees (FY)
149
Change (1Y)
−37 −19.89%
Revenue / Employee (1Y)
‪238.89 K‬ USD
Net income / Employee (1Y)
‪−139.05 K‬ USD

About Cytosorbents Corporation


Sector
Health Technology
Industry
Medical Specialties
CEO
Phillip P. Chan
Website
cytosorbents.com
Headquarters
Princeton
Founded
1997
FIGI
BBG000C3P8V0
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CTSO news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as CTSO.

Frequently Asked Questions


The current price of CTSO is 0.8701 USD — it has increased by 3.32% in the past 24 hours. Watch Cytosorbents Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cytosorbents Corporation stocks are traded under the ticker CTSO.
CTSO stock has fallen by −3.24% compared to the previous week, the month change is a −3.29% fall, over the last year Cytosorbents Corporation has showed a 4.83% increase.
We've gathered analysts' opinions on Cytosorbents Corporation future price: according to them, CTSO price has a max estimate of 10.00 USD and a min estimate of 1.00 USD. Watch CTSO chart and read a more detailed Cytosorbents Corporation stock forecast: see what analysts think of Cytosorbents Corporation and suggest that you do with its stocks.
CTSO reached its all-time high on Mar 24, 2015 with the price of 15.2400 USD, and its all-time low was 0.7000 USD and was reached on Jul 1, 2024. View more price dynamics on CTSO chart.
See other stocks reaching their highest and lowest prices.
CTSO stock is 3.44% volatile and has beta coefficient of 0.24. Track Cytosorbents Corporation stock price on the chart and check out the list of the most volatile stocks — is Cytosorbents Corporation there?
Today Cytosorbents Corporation has the market capitalization of ‪54.53 M‬, it has decreased by −18.94% over the last week.
Yes, you can track Cytosorbents Corporation financials in yearly and quarterly reports right on TradingView.
Cytosorbents Corporation is going to release the next earnings report on May 14, 2025. Keep track of upcoming events with our Earnings Calendar.
CTSO earnings for the last quarter are −0.03 USD per share, whereas the estimation was −0.05 USD resulting in a 40.00% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about Cytosorbents Corporation earnings.
Cytosorbents Corporation revenue for the last quarter amounts to ‪9.20 M‬ USD, despite the estimated figure of ‪10.25 M‬ USD. In the next quarter, revenue is expected to reach ‪9.21 M‬ USD.
CTSO net income for the last quarter is ‪−7.88 M‬ USD, while the quarter before that showed ‪−2.33 M‬ USD of net income which accounts for −237.77% change. Track more Cytosorbents Corporation financial stats to get the full picture.
No, CTSO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 13, 2025, the company has 149 employees. See our rating of the largest employees — is Cytosorbents Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cytosorbents Corporation EBITDA is ‪−17.30 M‬ USD, and current EBITDA margin is −42.24%. See more stats in Cytosorbents Corporation financial statements.
Like other stocks, CTSO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cytosorbents Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cytosorbents Corporation technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cytosorbents Corporation stock shows the sell signal. See more of Cytosorbents Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.